Supplemental Figure 1 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Abstract
Supplemental Figure 1: Overall survival of entire cohort from initiation of venetoclax.